Cargando…
Current Status and Advancements in Platelet-Rich Plasma Therapy
Platelet-rich plasma (PRP) as a treatment modality has been around for the last four decades, but only truly gained popularity over the last 10 to 15 years in medicine, in a variety of fields ranging from regenerative medicine to infertility treatment. It has gained popularity, especially in treatin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652151/ https://www.ncbi.nlm.nih.gov/pubmed/38021947 http://dx.doi.org/10.7759/cureus.47176 |
_version_ | 1785136148626014208 |
---|---|
author | Pretorius, Jacques Habash, Mohammed Ghobrial, Bishoy Alnajjar, Rafee Ellanti, Prasad |
author_facet | Pretorius, Jacques Habash, Mohammed Ghobrial, Bishoy Alnajjar, Rafee Ellanti, Prasad |
author_sort | Pretorius, Jacques |
collection | PubMed |
description | Platelet-rich plasma (PRP) as a treatment modality has been around for the last four decades, but only truly gained popularity over the last 10 to 15 years in medicine, in a variety of fields ranging from regenerative medicine to infertility treatment. It has gained popularity, especially in treating musculoskeletal conditions where the bulk of research has been performed and published. There is level I evidence available supporting its efficacy in the treatment of osteoarthritis (OA), epicondylitis, bursitis, compressive neuropathy, plantar fasciitis, muscular injuries and osteochondral lesions. Most published research with regards to PRP has been focused on knee OA (limited research in shoulder, elbow, and foot and ankle OA), lateral epicondylitis and carpal tunnel syndrome, whereas spinal and hand conditions have limited research available. Tendinopathies and partial tendon tears have conflicting evidence available, with level I evidence supporting PRP’s use in rotator cuff tendinopathies and tears, with contradictory level I evidence discouraging its use in patella and Achilles tendinopathies and tears. The available evidence regarding the use of PRP continues to produce conflicting results, but despite this, there is an ongoing increase in the popularity and use of PRP in patients with musculoskeletal conditions. |
format | Online Article Text |
id | pubmed-10652151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-106521512023-10-17 Current Status and Advancements in Platelet-Rich Plasma Therapy Pretorius, Jacques Habash, Mohammed Ghobrial, Bishoy Alnajjar, Rafee Ellanti, Prasad Cureus Physical Medicine & Rehabilitation Platelet-rich plasma (PRP) as a treatment modality has been around for the last four decades, but only truly gained popularity over the last 10 to 15 years in medicine, in a variety of fields ranging from regenerative medicine to infertility treatment. It has gained popularity, especially in treating musculoskeletal conditions where the bulk of research has been performed and published. There is level I evidence available supporting its efficacy in the treatment of osteoarthritis (OA), epicondylitis, bursitis, compressive neuropathy, plantar fasciitis, muscular injuries and osteochondral lesions. Most published research with regards to PRP has been focused on knee OA (limited research in shoulder, elbow, and foot and ankle OA), lateral epicondylitis and carpal tunnel syndrome, whereas spinal and hand conditions have limited research available. Tendinopathies and partial tendon tears have conflicting evidence available, with level I evidence supporting PRP’s use in rotator cuff tendinopathies and tears, with contradictory level I evidence discouraging its use in patella and Achilles tendinopathies and tears. The available evidence regarding the use of PRP continues to produce conflicting results, but despite this, there is an ongoing increase in the popularity and use of PRP in patients with musculoskeletal conditions. Cureus 2023-10-17 /pmc/articles/PMC10652151/ /pubmed/38021947 http://dx.doi.org/10.7759/cureus.47176 Text en Copyright © 2023, Pretorius et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Physical Medicine & Rehabilitation Pretorius, Jacques Habash, Mohammed Ghobrial, Bishoy Alnajjar, Rafee Ellanti, Prasad Current Status and Advancements in Platelet-Rich Plasma Therapy |
title | Current Status and Advancements in Platelet-Rich Plasma Therapy |
title_full | Current Status and Advancements in Platelet-Rich Plasma Therapy |
title_fullStr | Current Status and Advancements in Platelet-Rich Plasma Therapy |
title_full_unstemmed | Current Status and Advancements in Platelet-Rich Plasma Therapy |
title_short | Current Status and Advancements in Platelet-Rich Plasma Therapy |
title_sort | current status and advancements in platelet-rich plasma therapy |
topic | Physical Medicine & Rehabilitation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652151/ https://www.ncbi.nlm.nih.gov/pubmed/38021947 http://dx.doi.org/10.7759/cureus.47176 |
work_keys_str_mv | AT pretoriusjacques currentstatusandadvancementsinplateletrichplasmatherapy AT habashmohammed currentstatusandadvancementsinplateletrichplasmatherapy AT ghobrialbishoy currentstatusandadvancementsinplateletrichplasmatherapy AT alnajjarrafee currentstatusandadvancementsinplateletrichplasmatherapy AT ellantiprasad currentstatusandadvancementsinplateletrichplasmatherapy |